Recurrent Rectal Cancer Clinical Trial
Official title:
A Phase I/II Trial of Pertuzumab in Combination With Cetuximab and Irinotecan in Previously Treated Metastatic Colorectal Cancer
Monoclonal antibodies, such as pertuzumab and cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Giving pertuzumab together with cetuximab may kill more tumor cells. This phase I/II trial is studying the side effects and best dose of pertuzumab when given together with cetuximab and to see how well they work in treating patients with previously treated locally advanced or metastatic colorectal cancer
PRIMARY OBJECTIVES:
I. To determine the safety, tolerability, and recommended phase II dose of pertuzumab when
administered in combination with cetuximab in patients with cetuximab-refractory locally
advanced or metastatic colorectal cancer.
II. To evaluate the objective tumor response rate (RR) in patients treated with this
regimen.
SECONDARY OBJECTIVES:
I. To evaluate the median progression-free survival (PFS) of patients treated with this
regimen.
II. To evaluate the median overall survival (OS) of patients treated with this regimen.
III. To evaluate the RR, PFS, and OS in a subgroup of patients who are EGFR-positive by
immunohistochemistry.
IV. To explore the relationship between skin rash and the efficacy outcomes of RR, PFS, and
OS in these patients.
V. To explore the relationship between objective tumor response on positron emission
tomography (PET) scan after course two and the efficacy outcomes of RR, PFS, and OS in these
patients.
VI. To explore the relationship between a variety of laboratory correlates and the efficacy
outcomes of RR, PFS, and OS in these patients.
OUTLINE: This is a multicenter, phase I dose-escalation study of pertuzumab followed by a
phase II study.
PHASE I: Patients receive pertuzumab IV over 30-60 minutes on day 1. Patients also receive
cetuximab IV over 60-120 minutes on days 2, 8, and 15 of course 1 and on days 1, 8, and 15
in all subsequent courses.
Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
PHASE II: Patients receive treatment as in phase I. Pertuzumab is administered at the
recommended phase II dose (determined in phase I). Previously collected tumor tissue samples
are analyzed for correlative studies. Samples are analyzed for KRAS mutations via polymerase
chain reaction and pyrosequencing; EGFR expression via immunohistochemistry and fluorescent
in situ hybridization (FISH); HER receptor and ligand gene expression; and circulating tumor
cells. Additional blood samples are collected periodically to isolate circulating tumor
cells and are analyzed via FISH analysis.
After completion of study treatment, patients are followed at 30 days and then periodically
thereafter.
;
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01987726 -
Comprehensive Gene Sequencing in Guiding Treatment Recommendations Patients With Metastatic or Recurrent Solid Tumors
|
||
Active, not recruiting |
NCT00826540 -
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
|
Phase 2 | |
Completed |
NCT00025337 -
Combination Chemotherapy With or Without Bevacizumab Compared With Bevacizumab Alone in Treating Patients With Advanced or Metastatic Colorectal Cancer That Has Been Previously Treated
|
Phase 3 | |
Recruiting |
NCT04642924 -
SGM-101 in Locally Advanced and Recurrent Rectal Cancer
|
Phase 2/Phase 3 | |
Completed |
NCT01846520 -
Family Caregiver Palliative Care Intervention in Supporting Caregivers of Patients With Stage II-IV Gastrointestinal, Gynecologic, Urologic and Lung Cancers
|
N/A | |
Completed |
NCT01217450 -
Selumetinib and Cetuximab in Treating Patients With Refractory Solid Tumors
|
Phase 1 | |
Completed |
NCT01191684 -
Vaccine Therapy in Treating Patients With Colorectal, Stomach, or Pancreatic Cancer
|
Phase 1 | |
Terminated |
NCT01233505 -
Veliparib, Oxaliplatin, and Capecitabine in Treating Patients With Advanced Solid Tumors
|
Phase 1 | |
Terminated |
NCT01285102 -
Chemoembolization Using Irinotecan in Treating Patients With Liver Metastases From Metastatic Colon or Rectal Cancer
|
Phase 1 | |
Terminated |
NCT01238965 -
Panobinostat and Fluorouracil Followed By Leucovorin Calcium in Treating Patients With Stage IV Colorectal Cancer Who Did Not Respond to Previous Fluorouracil-Based Chemotherapy
|
Phase 1 | |
Completed |
NCT01037790 -
Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer
|
Phase 2 | |
Completed |
NCT00407654 -
VEGF Trap in Treating Patients With Previously Treated Metastatic Colorectal Cancer
|
Phase 2 | |
Completed |
NCT00091182 -
Oxaliplatin in Treating Young Patients With Recurrent Solid Tumors That Have Not Responded to Previous Treatment
|
Phase 2 | |
Terminated |
NCT00052585 -
Gefitinib and Combination Chemotherapy in Treating Patients With Advanced or Recurrent Colorectal Cancer
|
Phase 2 | |
Completed |
NCT00023933 -
Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Recurrent or Persistent Metastatic Colorectal Cancer
|
Phase 1 | |
Not yet recruiting |
NCT05076305 -
PelvEx 4: Advanced Pelvic Malignancy and the Role of the Multi-disciplinary Team Meeting
|
||
Completed |
NCT01740648 -
Trametinib, Fluorouracil, and Radiation Therapy Before Surgery in Treating Patients With Stage II-III Rectal Cancer
|
Phase 1 | |
Terminated |
NCT00397878 -
AZD0530 (NSC 735464) in Treating Patients With Previously Treated Metastatic Colon Cancer or Rectal Cancer
|
Phase 2 | |
Completed |
NCT00100841 -
Phase II Trial of FOLFOX6, Bevacizumab and Cetuximab in Patients With Colorectal Cancer
|
Phase 2 | |
Completed |
NCT00028496 -
Vaccine Therapy With or Without Sargramostim in Treating Patients With Advanced or Metastatic Cancer
|
Phase 1 |